1. Escargueil AE, Prado S, Dezaire A, Clairambault J, Larsen AK, et al. Genotype - or phenotype-targeting anticancer therapies? Lessons from tumor evolutionary biology. Curr Pharm Des 2016;22:6625-44.

2. Weinberg RA. Coming full circle-from endless complexity to simplicity and back again. Cell 2014;157:267-71.

3. Bertolaso M. Philosophy of Cancer. 1st ed. Netherlands: Springer; 2016.

4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.

5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.

6. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.

7. Heng HH, Bremer SW, Stevens JB, Karen JY, Liu G, et al. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol 2009;220:538-47.

8. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems 2006;83:81-90.

9. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.

10. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? Biomed Res Int 2014;2014:934038.

11. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324-9.

12. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.

13. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.

14. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.

15. Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer 2014;14:371-80.

16. Maddipati R, Stanger BZ. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov 2015;5:1086-97.

17. Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016;7:10690.

18. Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation egfr inhibitors. Clin Cancer Res 2016;22:4837-47.

19. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res 2018;24:6195-203.

20. Tie J, Wang Y, Tomasetti C, Li L, Springer S, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.

21. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 2017;114:10202-7.

22. Leung ML, Davis A, Gao R, Casasent A, Wang Y, et al. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 2017;27:1287-99.

23. Reiter JG, Makohon-Moore AP, Gerold JM, Bozic I, Chatterjee K, et al. Reconstructing metastatic seeding patterns of human cancers. Nat Commun 2017;8:14114.

24. Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, et al. Cervical cancer: a global health crisis. Cancer 2017;123:2404-12.

25. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-73.

26. Laplane L, Mantovani P, Adolphs R, Chang H, Mantovani A, et al. Why science needs philosophy. Proc Natl Acad Sci U S A 2019;116:3948-52.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us


All published articles will preserved here permanently:


All published articles will preserved here permanently: